Biotech Values

[genisi]

VRTX

Still, it seems odd that Graves would abandon one of the highest-profile jobs in the biotech industry without something else lined up, and it’s conceivable that there are skeletons in the Telaprevir closet that influenced Graves’ decision.

We agree on the 'odd' part but somehow, perhaps because I have a position and you don't, I don't think his departure has to do with skeletons in the Telaprevir closet.

We won’t know for sure until some time in 2011, when the FDA convenes an advisory panel for Telaprevir.

Let's wait and watch.